All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2018-02-07T09:06:45.000Z

Interventional strategies based on interim 18FFDG-PET for advanced stage HL

Feb 7, 2018
Share:

Bookmark this article

On the 21 January 2018, Sylvain Carras, from the Hematology Department of Grenoble University Hospital, France, and the GOELAMS group, had the results of their phase II multicenter study (NCT00920153) published advanced online in the Journal of Clinical Lymphoma, Myeloma & Leukemia. The study assessed interventional treatment strategies based on interim PET imaging results, for advanced stage Hodgkin lymphoma.

With the current medical improvements, the management of Hodgkin lymphoma (HL) is considered as standard practice for most patients but still fails to cure 20-30% of patients with advanced stage HL. The aim of this study was to assess the efficacy and safety of adaptive front- and second-line treatment strategies based on interim 18F-fluorodeoxyglucose positron emission tomography (18FFDG-PET) responses, in patients with advanced stage HL. The primary endpoints of the study included event-free survival (EFS), overall survival (OS) and safety.

Study overview

  • Total N = 51 patients with advanced HL (29 males; 22 females)
  • Median age = 41 (16–65)
  • All patients received two courses of VABEM chemotherapy: vindesine (1mg/m2), adriamycin (33mg/m2), carmustine (BCNU; 14mg/m2), etoposide (200mg/m2) and methylprednisolone (120mg/m2)
  • Following the two VABEM courses:
    • N = 49 patients received interim 18FFDG-PET scanning:
      • N = 37 (76%) had negative 18FFDG-PET scans:
        • Of those, n = 37 underwent one additional VABEM
        • Then n = 18 with initial bulky lesions (≥ 5cm) received additional radiotherapy
      • N = 12 (24%) had positive 18FDG-PET scans:
        • Of those, n = 11 received three courses of PDG: cisplatin (33mg/m2), gemcitabine (1000mg/m2) and dexamethasone (40mg) and peripheral blood stem-cell (PBSC) collection between the first and second PDG course
        • All 18FFDG-PET-positive patients finally received high dose therapy (HDT) and autologous stem cell transplantation (ASCT)

Key results

  • At the end of chemotherapy and radiotherapy:
    • Complete remission (CR): 88% (N=45/51)
    • Treatment failure: 12% (N=6/51)
  • After two VABEM courses:
    • CR= 76% (N = 37/49)
  • PDG CR = 83% (N = 10/12)
  • Median follow-up = 5.3 years
  • For the whole cohort:
    • 2-year EFS = 82.3% [95% CI (72.5–93.5%)]
    • 5-year EFS = 75.3% [95% CI (64–88.6%)]
    • 5-year OS = 85.3% [95% CI (76.3–96.1%)]
  • For 18FFDG-PET-negative patients:
    • 5-year EFS = 77.8% [95% CI (65.3–92.7%)]
    • 5-year OS = 88.2% [95% CI (78–99.8%)]
  • For 18FFDG-PET-positive patients:
    • 5-year EFS = 81.5% [95% CI (61.1–100%)]
    • 5-year OS = 91.7% [95% CI (77.3–100%)]

Safety

  • Deaths associated with treatment: 6% (3/51; 1 pulmonary embolism, 1 pulmonary fibrosis and 1 secondary leukemia)
  • Front-line-associated toxicity (VABEM):
    • ≥1 Grade 3-4 hematologic adverse events (AEs): 98% (50/51)
    • ≥1 Grade 3-4 non-hematologic AEs: 38% (19/51)
    • ≥ 1Grade 3-4 mucositis AEs: 35% (18/51)
    • ≥1 Grade 3-4 gastro-intestinal AEs: 8% (4/51)
  • PDG-associated toxicity (salvage therapy):
    • ≥1 Grade 3-4 hematologic AEs: 34% (11/32)
    • ≥1 Grade 3-4 non-hematologic AEs: 0% (0/32)

The authors concluded that adapting the treatment strategy, depending on the results of interim PET scanning, could be beneficial for the management of advanced stage HL. They also demonstrated the efficacy of sequential therapy with chemotherapy and ASCT in high-risk HL patients. According to the authors, despite the high and constant VABEM-related toxicity, their adapted strategy made the treatment manageable, with only a small percentage of treatment-related deaths (6%). Nevertheless, they reported that a longer-follow up study is necessary for the assessment of late toxicity. The authors proposed that this strategy should be targeted at high-risk advanced stage HL patients with positive interim PET findings, following fist-line chemotherapy.

  1. Carras S. et al. Interim PET response adapted strategy in untreated advanced stage Hodgkin Lymphoma: results of GOELAMS LH 2007 phase 2 multicentric trial. Journal of Clinical Lymphoma, Myeloma & Leukemia. 2018 Jan 21. doi: 10.1016/j.clml.2018.01.003. [Epub ahead of print]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
46 votes - 78 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox